Meiji Yasuda Asset Management Co Ltd. Purchases 119 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,314 shares of the biopharmaceutical company’s stock after purchasing an additional 119 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Regeneron Pharmaceuticals were worth $2,432,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. West Paces Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares during the period. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $26,000. Sachetta LLC increased its stake in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the period. Crewe Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $28,000. Finally, Lynx Investment Advisory purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at $33,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

REGN has been the topic of several recent analyst reports. Guggenheim raised their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Truist Financial reaffirmed a “buy” rating and set a $1,200.00 target price (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 2nd. Piper Sandler boosted their price target on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a report on Friday, August 23rd. TD Cowen raised their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Finally, Argus upped their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $1,111.30.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,026 shares of company stock worth $11,498,705. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ:REGN opened at $1,138.81 on Thursday. The business’s 50-day moving average is $1,129.45 and its 200 day moving average is $1,029.70. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The firm has a market capitalization of $125.48 billion, a P/E ratio of 33.64, a P/E/G ratio of 3.97 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. Regeneron Pharmaceuticals’s revenue was up 12.3% on a year-over-year basis. During the same period last year, the firm posted $8.79 EPS. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.